Market Movers (8-K)
See all →NYSE
TIC
Acuren CORPTIC Solutions announced robust second quarter 2026 revenue of $584.3 million and a 20% year-over-year increase in backlog, while reaffirming full-year financial outlook.
NYSE
TIC
Acuren CORPTIC Solutions, Inc. announced the results of its Annual Meeting of Stockholders held on July 1, 2026, including the election of directors and ratification of its independent auditor.
NYSE
TIC
Acuren CORPTIC Solutions announced record first quarter revenue of $488.0 million, but reported a net loss of $41.5 million, while reaffirming its full-year 2026 outlook.
NYSE
TIC
Acuren CORPTIC Solutions, Inc. filed pro forma financial statements for 2025, reflecting a net loss following its $1.7 billion acquisition of NV5 Global, Inc.
Worse than expected
Capital raise
NYSE
TIC
Acuren CORPTIC Solutions reported robust full-year 2025 financial results, including $1.5 billion revenue and $234.1 million Adjusted EBITDA, alongside the retirement of CEO Talman Pizzey and appointment of Benjamin Heraud.
Better than expected
Capital raise
NYSE
TIC
Acuren CORPTIC Solutions, Inc. announced its Board of Directors approved a stock dividend of 668,347 common shares for Series A preferred stockholders, calculated based on common stock appreciation.
Quarterly Earnings (10-Q)
NYSE
TIC
Acuren CORPTIC Solutions, Inc. reported a net loss for the second quarter of 2026, despite significant revenue growth driven by the NV5 acquisition, while also addressing material weaknesses in internal controls.
Worse than expected
NYSE
TIC
Acuren CORPTIC Solutions, Inc. reported a significant revenue increase driven by the NV5 acquisition, alongside a widened net loss and ongoing efforts to remediate internal control weaknesses.
Worse than expected
NYSE
TIC
Acuren CORPTIC Solutions, Inc. reported a net loss for Q3 2025 despite significant revenue and gross profit increases driven by the NV5 Global acquisition, while also disclosing material weaknesses in internal controls.
Capital raise
NYSE
TIC
Acuren CORPAcuren Corporation reported increased revenue but lower profitability for the second quarter and first half of 2025, while announcing a significant $1.7 billion acquisition of NV5 Global and an increase in its debt facilities.
Worse than expected
Capital raise
NYSE
TIC
Acuren CORPAcuren Corporation's Q1 2025 results show a revenue increase but a decrease in gross profit, and the company has announced a merger agreement with NV5 Global.
Capital raise
Worse than expected
Annual Reports (10-K)
NYSE
TIC
Acuren CORPTIC Solutions, Inc. has filed an Amendment No. 1 to its 2025 Form 10-K, primarily to include previously omitted Part III information and additional certifications.
NYSE
TIC
Acuren CORPTIC Solutions reports significant 2025 revenue growth driven by the NV5 acquisition, alongside a net loss and identified material weaknesses in internal controls over financial reporting.
Worse than expected
Capital raise
NYSE
TIC
Acuren CORPAcuren Corporation's 10-K filing summarizes the terms of its common stock, preferred stock, and warrants, highlighting voting rights, dividends, and potential dilution.
Insider Trading (Form 4)
See all →NYSE
TIC
Acuren CORPRory Cullinan, a Director of Acuren Corp, reported multiple transactions in common stock on July 31, 2026.
NYSE
TIC
Acuren CORPPeter A Hochfelder, a Director of Acuren Corp, reported multiple transactions in common stock on July 31, 2026.
NYSE
TIC
Acuren CORPJames E Lillie, a Director of Acuren Corp, reported multiple transactions in common stock on July 31, 2026.
NYSE
TIC
Acuren CORPElizabeth Meloy Hepding, a Director of Acuren Corp, reported multiple transactions in common stock on July 31, 2026.
NYSE
TIC
Acuren CORPAntoinette Cook Bush, a Director of Acuren Corp, reported multiple transactions in common stock on July 31, 2026.
NYSE
TIC
Acuren CORPDirector Talman Pizzey reports acquisition of 12,500 Restricted Stock Units in TIC Solutions, Inc. on July 1, 2026.
New Public Companies (S-1)
NYSE
TIC
Acuren CORPTIC Solutions, Inc. filed an S-1 registration statement for the resale of up to 20,833,333 shares of common stock by a selling stockholder, following recent acquisitions and a $250 million private placement.
Capital raise
Worse than expected
Schedule 13D - Activist Investments
NYSE
TIC
Acuren CORPSir Martin E. Franklin has significantly increased his voting control over TIC Solutions, Inc. common stock through a recent share distribution and an irrevocable proxy agreement.
NYSE
TIC
Acuren CORPAcuren Corp announced the completion of its merger agreement transactions, leading to a decrease in the percentage ownership of key reporting persons due to new share issuance.
Capital raise
NYSE
TIC
Acuren CORPAcuren Corp has filed an amendment to its Schedule 13D, revealing a definitive merger agreement to acquire NV5 Global, Inc. and a crucial voting support agreement from Mariposa Acquisition IX, LLC, a significant shareholder.
Capital raise
NYSE
TIC
Acuren CORPSCHEDULE 13D: Major Investor Sir Martin E. Franklin Discloses 16.4% Stake in Acuren Corp via Mariposa Acquisition IX, LLC
Sir Martin E. Franklin and Mariposa Acquisition IX, LLC have disclosed a beneficial ownership of 16.4% of Acuren Corp's Common Stock, signaling a significant investment position and potential future engagement with the company.
Capital raise
Schedule 13G - Passive Investments
See all →NYSE
TIC
Acuren CORPViking Global Investors LP filed an amendment to its Schedule 13G, reporting a 16.2% beneficial ownership stake in TIC Solutions, Inc. following the retirement of David C. Ott.
NYSE
TIC
Acuren CORPPermian Investment Partners, LP and affiliated funds have reported a significant beneficial ownership stake in TIC Solutions, Inc., totaling 9.9% of the company's common stock.
NYSE
TIC
Acuren CORPProgeny 3, Inc. and Jon Hemingway have filed an amended Schedule 13G, reporting a 6.9% beneficial ownership in TIC Solutions, Inc.
NYSE
TIC
Acuren CORPGates Capital Management and its affiliates have reduced their beneficial ownership in Acuren Corporation to 4.1% of common stock.
Worse than expected
NYSE
TIC
Acuren CORPGates Capital Management and affiliates disclose a 6.4% beneficial ownership stake in Acuren Corporation, totaling 7,771,068 shares.
NYSE
TIC
Acuren CORPBlackRock, Inc. has filed a Schedule 13G, reporting beneficial ownership of 5.7% of ACUREN CORP's common stock as of June 30, 2025.